Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge
STOCKHOLM, November 30th, 2020 – Moberg Pharma AB (publ) (”Moberg Pharma” or the ”Company”) has obtained a positive decision confirming that the Swedish Tax Agency shares the Company’s assessment that the Company’s proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, which means that the distribution will not be subject to taxation for the Company’s shareholders.
The board of directors of Moberg Pharma has proposed that the extraordinary general meeting to be held tomorrow, 1 December 2020, approves to distribute all of the Company’s shares in the subsidiary OncoZenge through a Lex Asea distribution with a contemplated record date in January/February 2021.
The Company now has a obtained a decision confirming that the Swedish Tax Agency shares the Company’s assessment that the Company’s proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act with, which means that the distribution will not be subject to taxation for Moberg Pharma’s shareholders.
For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-mail: mark.beveridge@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of Nasdaq Stockholm (OMX: MOB).
About OncoZenge, www.oncozenge.se
OncoZenge AB (publ) is a Swedish pharmaceutical company founded in 2020 through a spin-off from Moberg Pharma AB. The company collaborates with leading clinicians from Hvidovre Hospital in Denmark. OncoZenge develops better products for supportive care of cancer patients. Preparations are underway for Phase 3 of BupiZenge®, after leading Phase 2 data for pain relief in patients with oral mucositis.
Tags: